Loxo Oncology Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Loxo Oncology (LOXO) Prices 1.68M Common Stock Offering at $21.50/Share
May 12, 2016 9:51 AM EDTLoxo Oncology, Inc. (Nasdaq: LOXO) announced the pricing of its underwritten public offering of 1,675,000 shares of common stock at a public offering price of $21.50 per share. Gross proceeds to Loxo Oncology from this offering are expected to be approximately $36 million. Loxo Oncology intends to use the net proceeds from this offering for general corporate purposes, which may include funding research and development, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to its own, and capital expenditures.
Loxo Oncology also has granted the underwriters a 30-day... More
